Similarly, an exploratory analysis of the CAPItello-291 trial, which led to the approval of capivasertib in combination with fulvestrant for MBC patients whose tumours harbour oncogenic alterations of the PIK3CA, AKT, or PTEN gene, has suggested that capivasertib retains activity beyond AKT-pathway altered tumours [17]. Here, PTEN is linked to neoplasm.